Two-year results with 166Holmium-phytate treatment of chronic synovitis.: Phase I-IIa, randomized, increasing dosage, single-blind, placebo-controlled comparative study

被引：0
|
作者：
Szentesi, M
Takács, S
Farbaky, Z
Nagy, E
Környei, J
Antalffy, M
Törkö, J
Tóth, G
Jánoki, G
Balogh, L
Géher, P
机构：
[1] Semmelweis Univ, H-1085 Budapest, Hungary
[2] Inst Isotopes Co Ltd, Budapest, Hungary
[3] Natl FJC Res Inst Radiobiol & Radiohyg, Budapest, Hungary
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2004年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S478 / S478
页数：1
相关论文
共 50 条
  • [31] A Phase II Randomized Double-blind Placebo-controlled Single Center Study of Canakinumab Treatment of Adult Patients with Moderate to Severe Chronic Idiopathic Urticaria. (URTICANA-Study)
    Maul, J-T.
    Distler, M.
    Graf, N.
    Kolios, A.
    Navarini, A.
    Schmid-Grendelmeier, P.
    SWISS MEDICAL WEEKLY, 2019, : 8S - 8S
  • [32] Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study
    Kucher, Klaus
    Johns, Donald
    Wagner, Frank
    Abd-Elaziz, Khalid
    Derne, Caroline
    Sverdlov, Oleksandr
    Pfister, Christian U.
    Langguth, Berthold
    TINNITUS - AN INTERDISCIPLINARY APPROACH TOWARDS INDIVIDUALIZED TREATMENT: FROM HETEROGENEITY TO PERSONALIZED MEDICINE, 2021, 260 : 423 - 440
  • [33] Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT)
    Lebwohl, Mark
    Blauvelt, Andrew
    Paul, Carle
    Sofen, Howard
    Weglowska, Jolanta
    Piguet, Vincent
    Burge, Daniel
    Rolleri, Robert
    Drew, Janice
    Peterson, Luke
    Augustin, Matthias
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (02) : 266 - +
  • [34] A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects
    Fossler, Michael J.
    Schmith, Virginia
    Greene, Stephen A.
    Lohmer, Lauren
    Kramer, Michael S.
    Arscott, Kelly
    James, Ian E.
    Demitrack, Mark A.
    CNS DRUGS, 2020, 34 (08) : 853 - 865
  • [35] Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First-in-Human, Randomized, Single-Blind, Placebo-Controlled Study
    Connolly, Kathleen
    George, Richard
    Omar, Sami
    Matsson, Elin
    Astrand, Magnus
    Althage, Magnus
    Pettersen, Daniel
    Mohamed, Esha
    Fang, Kelly
    Lima, Joao A. C.
    Kujacic, Mirjana
    Odesjo, Helena
    Turton, Michelle
    Johannesson, Petra
    Gabrielsen, Anders
    Ufnal, Marcin
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (15):
  • [36] A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral bisphosphonate treatment on bone mineral density in osteopenic women receiving adjuvant aromatase inhibitors: Interim analysis of "BONADIUV" trial
    Scott, Vieri
    Meattini, Icro
    Cecchini, Sara
    De Feo, Maria Laura
    Saieva, Calogero
    Cardillo, Carla De Luca
    Livi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [37] ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IB/IIA DOSE-FINDING STUDY
    Li, R.
    Zhu, X.
    Liu, S.
    Zhang, X.
    Xie, C.
    Fu, Z.
    Huang, A.
    Sun, L.
    Liu, D.
    Zhao, J.
    Wu, L.
    Qin, Z.
    Li, S.
    Liu, Y.
    Li, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 210 - 210
  • [38] Two-Year Survival Follow-Up of the Randomized, Double-Blind, Placebo-Controlled Phase II Study of Radium-223 Chloride in Patients With Castration-Resistant Prostate Cancer and Bone Metastases
    Nilsson, Sten
    Franzen, Lars
    Parker, Christopher
    Tyrrell, Christopher
    Blom, Rene
    Tennvall, Jan
    Lennernas, Bo
    Petersson, Ulf
    Johannessen, Dag C.
    Sokal, Michael
    Pigott, Katharine
    O'Bryan-Tear, Charles Gillies
    Thuresson, Marcus
    Bolstad, Bjorg
    Bruland, Oyvind S.
    CLINICAL GENITOURINARY CANCER, 2013, 11 (01) : 20 - 26
  • [39] A single-blind, randomized, placebo-controlled phase II study to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: Final results of the single-center BONADIUV trial
    Livi, L.
    Saieva, C.
    Desideri, I.
    Scotti, V.
    Cardillo, C. De Luca
    Carta, G.
    Cecchini, S.
    Orzalesi, L.
    Sanchez, L. J.
    Casella, D.
    Bernini, M.
    Nori, J.
    Bianchi, S.
    De Feo, M. L.
    Meattini, I.
    CANCER RESEARCH, 2017, 77
  • [40] Intramuscular interferon beta-1a in combination with azathioprine and low-dose steroids for relapsing-remitting multiple sclerosis: Design and preliminary results of a two-year double-blind, randomized, placebo-controlled study
    Havrdova, E
    Ticha, V
    Novakova, I
    Meluzinova, E
    Krasensky, J
    Pasekova, E
    Seidl, Z
    Vaneckova, M
    Obenberger, J
    NEUROLOGY, 2001, 56 (08) : A356 - A356
12345